Key Protein Identified in Development of Alzheimer’s Disease
Scientists have discovered a key protein, Mdm2, in the development of Alzheimer’s disease that, when blocked, could potentially slow or halt the condition’s progress. This discovery was made through tests on mice, where deactivating Mdm2 stopped the destruction of dendritic spines and synapses, crucial for brain cell communication. Understanding the role of Mdm2 in Alzheimer’s progression could be crucial in developing treatments for the disease.
Effective Communication Techniques for Individuals with Dementia
Communication with individuals with dementia can be challenging, but learning specific techniques such as using simple language, maintaining a calm tone, and providing visual cues can make the process easier. Creating a comfortable environment and using positive reinforcement can also contribute to successful communication. Overall, patience, empathy, and a willingness to adapt to their specific needs are essential for effective communication with individuals with dementia.
Men on Viagra may reduce their Alzheimer’s risk – study
A recent study suggests that men who take drugs for erectile dysfunction, such as Viagra, may reduce their risk of developing Alzheimer’s disease. However, more research is needed to confirm these findings and understand the potential benefits and mechanisms of these drugs.
Nose Picking and Alzheimer’s Disease
A new study suggests that nose-picking may introduce pathogens that cause inflammation in the brain, increasing the risk of developing Alzheimer’s disease. The report’s authors urge people to stop picking their nose, as it may lead to neuroinflammation and the production of beta-amyloid, a protein associated with Alzheimer’s.
7 Healthy Habits to Support Brain Health in Your 40s
While many people in their 40s are aware of Alzheimer’s disease, it probably doesn’t feel like an immediate threat. That makes sense, because most people with the condition don’t show symptoms until they’ve passed their 65th birthday, according to the…
Biogen Terminates Phase 4 Trial for Aducanumab, Transfers Ownership Rights
Biogen, the pharmaceutical company behind the development of aducanumab, has announced the termination of the Phase 4 trial mandated by the FDA for the drug. Aducanumab, a monoclonal antibody targeting beta-amyloid, had received accelerated approval in 2021. However, the company…
First-Ever Transmitted Cases of Alzheimer’s Linked to Growth Hormone Treatment
Scientists have made a groundbreaking discovery in the field of Alzheimer’s disease, documenting the first-ever transmitted cases of the condition. The cases are linked to a now-discontinued medical procedure involving the use of growth hormone derived from human cadavers. The…
Obesity Drugs’ Superpower: Taming Inflammation
Obesity drugs have another superpower: taming inflammation The latest generation of anti-obesity drugs has taken the world by storm, thanks to their effectiveness at treating diabetes and reducing weight. But these drugs also have a less well-known superpower: the ability…
Simple Blood Tests Could Revolutionize Alzheimer’s Diagnosis
The possibility of simple blood tests to help diagnose Alzheimer’s disease faster has been given a boost after researchers revealed evidence that they can rival costly brain scans or painful lumbar punctures for accuracy. Recent studies have brought the possibility…
Study Links Short Strands of Toxic RNAs to Brain Cell Death in Alzheimer’s Disease
Scientists from Northwestern University and elsewhere have published details of a study that links short strands of toxic RNAs to brain cell death and DNA damage in Alzheimer’s disease and aged brains. The paper, which is titled, “Death induced by…